Analyst Roanna Ruiz of Leerink Partners reiterated a Buy rating on Xeris Pharmaceuticals (XERS – Research Report), retaining the price target of $6.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Roanna Ruiz’s rating is based on a combination of factors that highlight the positive outlook for Xeris Pharmaceuticals. The company has provided a more precise revenue guidance for FY25, which suggests confidence in their financial projections. Additionally, the stronger than expected revenues from Recorlev in the first quarter of 2025 indicate a promising growth trajectory for this product, particularly in treating endogenous Cushing’s syndrome.
Moreover, despite facing generic competition, Keveyis revenues have shown resilience, maintaining their durability quarter over quarter. Xeris is also making strategic advancements in their clinical pipeline, notably with the development of the XP-8121 program for hypothyroidism. These factors, along with anticipated updates at the upcoming Analyst & Investor Day, contribute to the positive sentiment and Buy rating for Xeris Pharmaceuticals.
In another report released on May 9, Oppenheimer also maintained a Buy rating on the stock with a $7.00 price target.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of XERS in relation to earlier this year.